Comparison of Quadratus Lumborum Block Types | NCT04588389

Comparison of Quadratus Lumborum Block Types | NCT04588389 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Group 1 Standard of Care	Active Comparator	Group I will receive the standard of care multimodal pharmacological management.	Drug: Multimodal Pharmacological Management
Group 2 Standard of Care + Quadratus Lumborum Block II	Experimental	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block.	Drug: Ropivacaine injection Location 1 Drug: Multimodal Pharmacological Management
Group 3 Standard of Care + Quadratus Lumborum Block III	Experimental	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient.	Drug: Ropivacaine injection Location 2 Drug: Multimodal Pharmacological Management

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Ropivacaine injection Location 1	Drug	Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1	Group 2 Standard of Care + Quadratus Lumborum Block II

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Opioid Consumption	Dose of the opioids consumed	12 hours
Opioid Consumption	Dose of the opioids consumed	24 hours
Opioid Consumption	Dose of the opioids consumed	36 hours
Opioid Consumption	Dose of the opioids consumed	48 hours

Secondary Outcomes

Measure	Description	Time Frame
Pain Scale	Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.	0 Hours
Pain Scale	Numerical Pain Scale Rating of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.

Contacts/Locations Module

Name	Affiliation	Role
Eman Nada, MD	University of Massachusetts, Worcester	Principal Investigator
Alexander Chan, MD	University of Massachusetts, Worcester	Principal Investigator

Facility	Status	City	State	ZIP	Country	Contacts
UMASS Memorial Medical Center		Worcester	Massachusetts	01605	United States

Arm/Group Information

ID	Title	Description
FG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
FG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
FG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Periods

Title

Milestones

Reasons Not Completed

Overall Study

Type	Comment	Milestone Data
STARTED		FG0002 subjects FG0014 subjects FG0023 subjects
COMPLETED		FG0000 subjects FG0014 subjects FG0023 subjects
NOT COMPLETED		FG0002 subjects FG0010 subjects FG0020 subjects

Type	Comment	Reasons
Issues with anesthesia during surgery		FG0002 subjects FG0010 subjects FG0020 subjects

Baseline Characteristics Module

Arm/Group Information

ID	Title	Description
BG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
BG001	Group 2 Standard of Care + Quadratus Lumborum Block II

Units	Counts
Participants	BG000

Baseline Measures

Title	Description	Population Description	Parameter Type	Dispersion Type	Unit of Measure	Calculate Percentage	Denominator Units Selected	Denominators	Classes
Age, Categorical			Count of Participants

Outcome Measures Module

Outcome Measures

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Opioid Consumption

Dose of the opioids consumed

No data was collected on Participants in Group 1 and were excluded from analysis population as there were issues with anesthesia. One participant received a large amount of local anesthetics by surgeon and the other received ketamine in anesthesia.

Posted

Mean

Full Range

morphine milligram equivalents

12 hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II

Adverse Events Module

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management

More Info Module

Certain Agreements

Title	Organization	Phone	Extension	Email
Dr Alexander Chan for Eman Nada, MD	UMass Chan Medical School	7743030338		alexander.chan@umassmemorial.org

Uploaded Document Information

Type	Includes Protocol	Includes SAP	Includes ICF	Document Label	Document Date	Document Uploaded Date	Document File Name
Prot_SAP	Yes	Yes	No	Study Protocol and Statistical Analysis Plan	Sep 17, 2018	Jun 22, 2022	Prot_SAP_000.pdf
ICF	No	No	Yes	Informed Consent Form	Apr 20, 2021	May 5, 2023	ICF_002.pdf

Condition Browse Module

ID	Term
D010146	Pain
D007405	Intervertebral Disc Displacement

ID	Term
D009461	Neurologic Manifestations
D012816	Signs and Symptoms
D013568	Pathological Conditions, Signs and Symptoms
D013122	Spinal Diseases

Intervention Browse Module

ID	Term
D008012	Lidocaine
D059039	Standard of Care

ID	Term
D000083	Acetanilides
D000813	Anilides
D000577	Amides
D009930	Organic Chemicals
D000814

Race (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
American Indian or Alaska Native	BG0010 BG0020 BG0030
Asian	BG0010 BG0020 BG0030
Native Hawaiian or Other Pacific Islander	BG0010 BG0020 BG0030
Black or African American	BG0010 BG0020 BG0030
White	BG0010 BG0020 BG0030
More than one race	BG0010 BG0020 BG0030
Unknown or Not Reported	BG0014 BG0023 BG0037

Primary

Opioid Consumption

Dose of the opioids consumed

Posted

Mean

Full Range

Morphine milligram equivalents

24 hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG00131(7.5 to 56.25) OG00220(15 to 37.5)

Primary

Opioid Consumption

Dose of the opioids consumed

Posted

Mean

Full Range

Morphine milligram equivalents

36 hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG00135.625(15 to 52.5) OG00220(7.5 to 30)

Primary

Opioid Consumption

Dose of the opioids consumed

Posted

Mean

Full Range

Morphine milligram equivalents

48 hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG00131.875(15 to 45) OG00225(15 to 30)

Secondary

Pain Scale

Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.

Posted

Mean

Full Range

score on a scale

0 Hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG0018(5 to 10) OG0023.67(0 to 7)

Secondary

Pain Scale

Numerical Pain Scale Rating of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.

Posted

Mean

Full Range

score on a scale

1 Hour

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG0014.75(3 to 8) OG0022(0 to 4)

Secondary

Pain Scale

Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.

Posted

Mean

Full Range

score on a scale

6 Hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG0015.25(3 to 8) OG0022.33(0 to 4)

Secondary

Pain Scale

Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.

Posted

Mean

Full Range

score on a scale

12 Hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG0015.25(4 to 8) OG0025.33(4 to 8)

Secondary

Pain Scale

Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.

Posted

Mean

Full Range

score on a scale

18 Hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG0016(4 to 9) OG0025.33(3 to 8)

Secondary

Pain Scale

Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.

Posted

Mean

Full Range

score on a scale

24 Hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG0015.75(4 to 7) OG0024.67(3 to 6)

Secondary

Pain Scale

Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.

Posted

Mean

Full Range

score on a scale

30 Hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG0014.75(0 to 8) OG0022.3(0 to 5)

Secondary

Pain Scale

Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.

Posted

Mean

Full Range

score on a scale

36 Hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG0016.25(4 to 9) OG0026.33(4 to 10)

Secondary

Pain Scale

Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.

Posted

Mean

Full Range

score on a scale

42 Hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG0015.25(4 to 7) OG0022(0 to 6)

Secondary

Pain Scale

Numerical Pain Scale Rating, likert scale of 0-10 with a 0 indicating absence of pain and 10 indicating worst pain imaginable.

Not able to collect data on a Group 2 participant due to timing and discharge.

Posted

Mean

Full Range

score on a scale

48 hours

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0013 OG0023

Title

Denominators

Categories

Title	Measurements
	OG0016(4 to 8) OG0023.667(3 to 4)

Secondary

Discharge Opioid Use

The amount of left-over opioid pills at 2 weeks in the follow up visit.

Posted

2 weeks

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0010 OG0020

Secondary

Number of Participants Experiencing Side Effects

Number of Participants who experienced side effects.

Posted

Number

participants

Up to 1 week

ID	Title	Description
OG000	Group 1 Standard of Care	Group I will receive the standard of care multimodal pharmacological management. Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG001	Group 2 Standard of Care + Quadratus Lumborum Block II	Group II will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum II local anesthetic block. Ropivacaine injection Location 1: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 1 Multimodal Pharmacological Management: standard of care multimodal pharmacological management
OG002	Group 3 Standard of Care + Quadratus Lumborum Block III	Group III will receive standard of care multimodal pharmacological management plus the Quadratus Lumborum III local anesthetic block. We will measure opioid use, pain, and side effects in each patient. Ropivacaine injection Location 2: Ropivacaine .5% and lidocaine 1% to the area behind the muscle Quadratus Lumborum location 2 Multimodal Pharmacological Management: standard of care multimodal pharmacological management

Units	Counts
Participants	OG0000 OG0014 OG0023

Title

Denominators

Categories

Title	Measurements
	OG0014 OG0023